Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort

[1]  M. Ronot,et al.  Management of splanchnic vein thrombosis , 2023, JHEP reports : innovation in hepatology.

[2]  B. George,et al.  Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing , 2022, Annals of Hematology.

[3]  A. Mead,et al.  In utero origin of myelofibrosis presenting in adult monozygotic twins , 2022, Nature Medicine.

[4]  P. Di Carlo,et al.  Circulating Endothelial Cell Levels Correlate with Treatment Outcomes of Splanchnic Vein Thrombosis in Patients with Chronic Myeloproliferative Neoplasms , 2022, Journal of personalized medicine.

[5]  L. Baldini,et al.  Triple-Negative Essential Thrombocythemia: Clinical-Pathological and Molecular Features. A Single-Center Cohort Study , 2021, Frontiers in Oncology.

[6]  V. de Lédinghen,et al.  Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses. , 2020, Blood advances.

[7]  D. Colomer,et al.  Next generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis. , 2020, Journal of hepatology.

[8]  J. González-Martín,et al.  Thrombotic Risk Detection in Patients with Polycythemia Vera: The Predictive Role of DNMT3A/TET2/ASXL1 Mutations , 2020, Cancers.

[9]  M. Dimopoulos,et al.  Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma. , 2020, Blood advances.

[10]  M. Cazzola,et al.  Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases , 2019, American journal of hematology.

[11]  U. Gianelli,et al.  Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic Options , 2019, International journal of molecular sciences.

[12]  E. van den Berg,et al.  European recommendations and quality assurance for cytogenomic analysis of haematological neoplasms , 2019, Leukemia.

[13]  P. Campbell,et al.  Classification and Personalized Prognosis in Myeloproliferative Neoplasms , 2018, The New England journal of medicine.

[14]  P. Bianchi,et al.  Heterogeneity among splanchnic vein thrombosis associated with myeloproliferative neoplasms. , 2018, European journal of internal medicine.

[15]  P. Kamath,et al.  Splanchnic vein thrombosis in patients with myeloproliferative neoplasms: The Mayo clinic experience with 84 consecutive cases , 2018, American journal of hematology.

[16]  M. Moarii,et al.  Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups , 2017, Leukemia.

[17]  S. Swerdlow.  WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .

[18]  S. Gabriel,et al.  Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease , 2017, The New England journal of medicine.

[19]  J. How,et al.  Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease , 2017, Therapeutic advances in hematology.

[20]  Matthew A. Cooper,et al.  Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice , 2017, Science.

[21]  M. Cazzola,et al.  Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms , 2017, American journal of hematology.

[22]  M. Griesshammer,et al.  Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients , 2016, Blood Cancer Journal.

[23]  C. Tyler-Smith,et al.  Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies. , 2016, Blood.

[24]  B. Ebert,et al.  Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. , 2015, Blood.

[25]  C. Augello,et al.  Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myeloproliferative neoplasms associated with splanchnic vein thrombosis. , 2015, Leukemia research.

[26]  Paola Guglielmelli,et al.  Effect of mutation order on myeloproliferative neoplasms. , 2015, The New England journal of medicine.

[27]  S. Langabeer,et al.  Incidence of CALR mutations in patients with splanchnic vein thrombosis , 2015, British journal of haematology.

[28]  J. Chi,et al.  Characterization of gene mutations and copy number changes in acute myeloid leukemia using a rapid target enrichment protocol , 2015, Haematologica.

[29]  D. Colomer,et al.  Role of calreticulin mutations in the aetiological diagnosis of splanchnic vein thrombosis. , 2015, Journal of hepatology.

[30]  C. Augello,et al.  Molecular analyses in the diagnosis of myeloproliferative neoplasm-related splanchnic vein thrombosis , 2015, Annals of Hematology.

[31]  M. McCarthy,et al.  Age-related clonal hematopoiesis associated with adverse outcomes. , 2014, The New England journal of medicine.

[32]  A. Tong,et al.  Elevated serum erythropoietin in a patient with polycythaemia vera presenting with Budd-Chiari syndrome , 2014, BMJ Case Reports.

[33]  T. Barbui,et al.  Cerebral vein thrombosis in patients with Philadelphia‐negative myeloproliferative neoplasms An European Leukemia Net study , 2014, American journal of hematology.

[34]  S. Gabriel,et al.  Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. , 2014, The New England journal of medicine.

[35]  W. Ageno,et al.  Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases. , 2014, Thrombosis research.

[36]  E. Solary,et al.  The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases , 2014, Leukemia.

[37]  T. Barbui,et al.  Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: a consensus-based SIE, SIES, GITMO position paper. , 2014, Leukemia research.

[38]  G. Superti-Furga,et al.  Somatic mutations of calreticulin in myeloproliferative neoplasms. , 2013, The New England journal of medicine.

[39]  J. D. Fitzpatrick,et al.  Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. , 2013, The New England journal of medicine.

[40]  T. Barbui,et al.  Are MPNs Vascular Diseases? , 2013, Current Hematologic Malignancy Reports.

[41]  R. Silver,et al.  Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis. , 2013, Blood.

[42]  A. Burroughs,et al.  Splanchnic vein thrombosis in myeloproliferative neoplasms , 2013, British journal of haematology.

[43]  R. Kralovics,et al.  Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. , 2013, Blood.

[44]  M. Paulli,et al.  Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation. , 2013, Blood.

[45]  T. Barbui,et al.  Cardiovascular events and intensity of treatment in polycythemia vera. , 2013, The New England journal of medicine.

[46]  D. Valla,et al.  Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. , 2012, Blood.

[47]  A. Falanga,et al.  Thrombotic disease in the myeloproliferative neoplasms. , 2012, Hematology. American Society of Hematology. Education Program.

[48]  G. Mufti,et al.  Prevalence and clinical outcomes of the 46/1 haplotype, Janus kinase 2 mutations, and ten‐eleven translocation 2 mutations in budd‐chiari syndrome and their impact on thrombotic complications post Liver Transplantation , 2012, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[49]  A. Børresen-Dale,et al.  The Life History of 21 Breast Cancers , 2012, Cell.

[50]  Ingo Ruczinski,et al.  Detectable clonal mosaicism from birth to old age and its relationship to cancer , 2012, Nature Genetics.

[51]  W. Ageno,et al.  Splanchnic vein thrombosis: new risk factors and management. , 2012, Thrombosis research.

[52]  F. Leebeek,et al.  Long‐term follow‐up of patients with portal vein thrombosis and myeloproliferative neoplasms , 2011, Journal of thrombosis and haemostasis : JTH.

[53]  R. Silver,et al.  The treatment of essential thromobocytosis revisited. , 2011, Blood.

[54]  T. Barbui,et al.  Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. , 2011, Blood.

[55]  M. Margaglione,et al.  New TET2 gene mutations in patients with myeloproliferative neoplasms and splanchnic vein thrombosis , 2010, Journal of thrombosis and haemostasis : JTH.

[56]  D. Hodge,et al.  Survival and recurrence in patients with splanchnic vein thromboses. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[57]  T. Barbui,et al.  Thrombosis in primary myelofibrosis: incidence and risk factors. , 2009, Blood.

[58]  J. Soulier,et al.  Mutation in TET2 in myeloid cancers. , 2009, The New England journal of medicine.

[59]  F. Rosendaal,et al.  Etiology, management, and outcome of the Budd-Chiari syndrome. , 2009, Annals of internal medicine.

[60]  P. Chiusolo,et al.  Absence of the JAK2 exon 12 mutations in patients with splanchnic venous thrombosis and without overt myeloproliferative neoplasms , 2009, American journal of hematology.

[61]  A. Zanella,et al.  The significance of bone marrow biopsy and JAK2V617F mutation in the differential diagnosis between the "early" prepolycythemic phase of polycythemia vera and essential thrombocythemia. , 2008, American Journal of Clinical Pathology.

[62]  S. Chevret,et al.  The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. , 2008, Blood.

[63]  G. Barosi,et al.  MPL and JAK2 exon 12 mutations in patients with the Budd-Chiari syndrome or extrahepatic portal vein obstruction. , 2008, Blood.

[64]  Y. Bayraktar,et al.  JAK2V617F Mutation in Patients with Portal Vein Thrombosis , 2008, Digestive Diseases and Sciences.

[65]  P. Campbell,et al.  Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment , 2008, Leukemia.

[66]  P. Mannucci,et al.  Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis , 2006, Hepatology.

[67]  A. Tefferi,et al.  Abdominal vein thrombosis in essential thrombocythemia: prevalence, clinical correlates, and prognostic implications , 2006, European journal of haematology.

[68]  J. D. van der Walt,et al.  Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. , 2005, The New England journal of medicine.

[69]  T. Barbui,et al.  Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study , 2005, British journal of haematology.

[70]  T. Barbui,et al.  Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  P. Campbell,et al.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.

[72]  L. Marsano,et al.  Complications of cirrhosis. , 2003, The Journal of the Kentucky Medical Association.

[73]  G. Leone,et al.  An atypical myeloproliferative disorder with high thrombotic risk and slow disease progression , 2006 .

[74]  D. Valla,et al.  Etiology of portal vein thrombosis in adults. A prospective evaluation of primary myeloproliferative disorders. , 1988, Gastroenterology.